___

• KAYNAKLAR
• Günay Y, Güler N, Akyıldız M ve ark. Hepatosellüler karsinoma ve canlı vericili karaciğer nakli:kanser nüksü ve hasta sağkalımını etkileyen faktörler. Tek merkez deneyimi. Gaziantep Tıp Dergisi 2013;19(3):173-9.
• Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitontreatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43(3):425-34.
• Balkan BM, Sel T. Vitamin C’nin HepG2 hücrelerinde apoptozis üzerine etkileri. Ankara Üniversitesi Veteriner Fakültesi Dergisi 2014;61:237-41.
• Reynolds CP, Maurera, BJ, Kolesnick RN. Ceramide synthesisand metabolism as a target for cancer therapy. Cancer Lett 2004;206:169–80.
• Albi E and Mgni MV. Sphingolipid metabolism inhibitors andcell function. The Open Enzyme Inhibition Journal 2008;1,72-9.
• Beckham TH, Elojeimy S, Cheng JC, et al. Targetingsphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets. 2010;14:529-39.
• Chalfant CE, Rathman K, Pinkerman RL and et al. De novoceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 2002;277,12587-95.
• Mao C, Obeid LM. Ceramidases: regulators of cellular responses mediated by ceramide, sphingosine, and sphingosine-1-phosphate. Biochim Biophys Acta 2008;1781:424-34.
• Strelow A, Bernardo K, Klages SA, et al. Overexpression ofacid ceramidase protects from tumor necrosis factor induced cell death. J Exp Med 2000;192:601-11.
• Kolesnick R. The therapeutic potential of modulating theceramide/sphingomyelin pathway, J Clin Invest 2000;110:3–8.
• Liu X, Cheng JC, Turner LS, et al. Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 2009;13:1449-1458.
• Mahdy AEM, Cheng JC, Li Jun. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation:AC inhibition, a potential radiosensitizier. Mol Ther 2009;17:430-8.
• Huerta S, Gaulet EJ, Huerta-Yepez S, Livingston EH. Screening and detection of apoptosis. J Surg Res 2007;139:143–56
• Engedal N, Saatcioglu F. Ceramide-induced cell death in the prostate cancer cell line LNCaP has both necrotic and apoptotic features. Prostate 2001;46:289-97
• Realini N, Solorzano C, Pagliuca C, et al. Discovery ofhighly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity. Scientific Reports 2013;3:1-7.
• Hu W, Xu R, Sun W, et al. Alkaline ceramidase 3 hydolyzesunsaturated lon chain ceramides and its down regulation inhibits both cell proliferation and apoptosis. J Biol Chem 2010;285:7964-76.
• Zweelan Ratnan S, Quian C, Yokomiza, A, et al. Human acidceramidase is overexpressed but not mutataed in prostate cancer, Genes, Chromosomes and Cancer. 2000;29:137-46.
• Proksch D, Klein JJ, Arenz C, et al. Potent inhibition of acidceramidase by novel B-13 analogues. J Lipids 2011;971618:1-8.
• Holman DH, Turner LS. Lysosomotropic acid ceramidaseinhibitor induces apoptosis in prostate cancer cells. Cancer Chem Pharm 2008; 61:231-42.
• Saad AF, Meachham WD, Bai A, et al.. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 2007;9:1455-60.
• Morales A, Paris R, Villanueva A, et al. Pharmacologicalinhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo. Oncogene 2006: 26;905-16.
• Domracheva I, Muhamadejev R, Petrova M, et al. 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC) increases Carmofur stability and in vitro antiproliferative effect. Toxicology report 2015: 2, 377-383.60